Interleukin 2 (IL-2) is a growth factor for T and natural killer cells, promotes proinflammatory cytokines, and can lead to durable responses in patients with melanoma. Vascular endothelial growth factor (VEGF) promotes angiogenesis and modulates host innate and adaptive immunity. High VEGF levels were found to be associated with nonresponse to IL-2. Ziv-aflibercept may deplete VEGF and thereby enhance antitumor T-cell responses, thus supporting a combination immunotherapeutic strategy with IL-2. METHODS: NCI 8628 was a phase 2 trial of ziv-aflibercept and IL-2 (arm A) versus IL-2 alone (arm B) randomized at 2:1, respectively. Eligible patients had inoperable American Joint Committee on Cancer stage III or stage IV melanoma. The primary endpoint was progression-free survival (PFS). RESULTS: A total of 89 patients were enrolled and 84 patients were treated. The median followup was 41.4 months. Among treated patients (55 patients in arm A and 29 patients in arm B), PFS was significantly improved in favor of arm A, with a median of 6.9 months (95% confidence interval [95% CI], 4.1-8.7 months) versus 2.3 months (95% CI, 1.6-3.5 months) (P<.001). No significant difference was noted with regard to overall survival, with a median of 26.9 months (95% CI, 14.4-63.6 months) for arm A and 24.2 months (95% CI, 11.3-36.4 months) for arm B. The response rate (according to Response Evaluation Criteria In Solid Tumors [RECIST]) was 22% in arm A (4 complete responses [CRs] and 8 partial responses [PRs]) and 17% in arm B (1 CR and 4 PRs). Stable disease or PR or CR was noted in 65% of patients in arm A and 48% of patients in arm B. The combination was found to be superior to monotherapy in patients with high and low levels of serum VEGF and VEGF receptor 2. Adverse events were consistent with the expected profiles of monotherapy with IL-2 and ziv-aflibercept. CONCLUSIONS: Ziv-aflibercept and IL-2 were found to significantly improve PFS compared with IL-2 alone, thereby meeting the primary endpoint of the current study. These findings support further study of immunotherapeutic combination strategies involving VEGF inhibitors. Cancer 2018;124:4332-4341.
INTRODUCTION
The prior lack of progress in the systemic management of metastatic melanoma, which lasted for several decades, recently has changed dramatically, driven by a deepening understanding of the biology and host immunology of melanoma. 1, 2 This progress at the molecular level has been translated into the clinic with the advent of multiple new molecularly targeted agents (BRAF and MEK kinase inhibitors) and immune checkpoint modulators (cytotoxic T-lymphocyteassociated protein 4 [CTLA4] and programmed cell death protein 1 [PD-1]-blocking antibodies) that have made major improvements in disease control and the survival of patients with metastatic melanoma. In practice, the first-line therapy for patients with metastatic melanoma currently consists primarily of immune checkpoint inhibitor or targeted kinase inhibitor therapy for patients with BRAF-mutant melanoma.
Interleukin 2 (IL-2) plays a central role in immune regulation because it affects the survival of key cells of the immune system that are responsible for the antitumor cytotoxicity of T lymphocytes and natural killer cells, and it has a cofactor role in the activation of B cells and macrophages. 3 Initial studies with high-dose bolus (HD) IL-2 used doses of
Cancer November 15, 2018 600,000 to 720,000 U/kg every 8 hours from days 1 to 5 (cycle 1) and days 15 to 19 (cycle 2), with a maximum of 14 doses per cycle or 28 doses per course (1 course was equal to 2 cycles). A review of 8 clinical trials (270 patients) conducted between 1985 and 1993 reported an objective response rate (RR) of 16%, with durable responses noted in 4% of patients. 4 The median response duration was 8.9 months (range, 4 to ≥106 months). Among responding patients, 28% (including 59% of those patients who had achieved a complete response [CR] ) remained free of disease progression at a median follow-up of 62 months. Furthermore, no patient who had responses lasting >30 months had developed disease recurrence, suggesting the possibility that these patients may be "cured." 5 A proteomic analysis of the serum of patients with metastatic melanoma and renal cell carcinoma who were treated with HD IL-2 identified vascular endothelial growth factor (VEGF) as a predictor of response to IL-2 therapy. 6 Patients with serum VEGF levels >125 pg/mL did not respond to HD IL-2 and elevated levels also were found to be associated with a significantly worse overall survival (OS).
The VEGF family plays a critical role in mediating angiogenesis, lymphangiogenesis, and vasculogenesis and has an impact on host innate and adaptive immunity. 7, 8 The role of elevated VEGF levels on tumor angiogenesis is well documented, and high circulating levels of VEGF recently were reported to be associated with poor prognosis in patients with metastatic melanoma. 9 VEGF has been shown to block the maturation of dendritic cells and to inhibit the effective priming of T-cell responses. 10, 11 These data support an important role for VEGF in the progression of cancer and the evasion of antitumor immunity. A therapeutic strategy designed to deplete high serum VEGF levels prior to the administration of HD IL-2 may reverse the negative impact of high serum VEGF on dendritic cell maturation and T-cell priming, thereby allowing more effective antitumor T-cell cytotoxicity induced by HD IL-2. As a potent VEGF inhibitor, ziv-aflibercept is a fusion protein of human immunoglobulin (Ig) G1 Fc portion and extracellular ligand-binding domains of VEGF receptor 1 (VEGFR1) and VEGFR2. 12 It acts as a high-affinity soluble decoy VEGFR. We previously reported a phase 2 study of ziv-aflibercept in patients with inoperable stage III or stage IV melanoma that demonstrated evidence of clinical activity, including a median OS of 16.3 months (95% confidence interval [95% CI], 9.2 months to not reached) and a median progression-free survival (PFS) of 3.7 months (95% CI, 2.8-6.8 months). 13 We hypothesized that sequential biotherapy with ziv-aflibercept and HD IL-2 will lead to improved antitumor efficacy compared with the use of HD IL-2 alone.
MATERIALS AND METHODS

Eligibility
Eligibility Figure 1 . Patients randomized to the combination arm (arm A) received up to 3 courses of immunotherapy. Each course consisted of 2 cycles of HD IL-2 at a dose of 600,000 IU/kg intravenously every 8 hours for up to 14 doses (first cycle), followed by a period of 1-week rest and readmission for treatment with HD IL-2 (second cycle). Ziv-aflibercept was given concurrently at a dose of 3 mg/kg intravenously every 2 weeks, starting 2 weeks prior to the initial administration of IL-2 in course 1. In the absence of disease progression, maintenance ziv-aflibercept was administered at a dose of 4 mg/kg every 2 weeks after the completion of IL-2. In the treatment arm with HD IL-2 alone (arm B), patients received HD IL-2 for a maximum of 3 courses (6 cycles).
Patients who experienced toxicity were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (version 4.0) and were managed in accordance with toxicity-specific management and dose modification guidelines provided in the study protocol.
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Endpoints
The primary objective of the current study was to compare PFS between the combination and HD IL-2-alone arms. Secondary objectives were to compare the RR and OS and to assess toxicity. PFS was defined as the time from randomization to disease progression or death without disease progression. The RR was assessed using RECIST criteria (version 1.1).
14 OS was defined as the time from randomization to death from any cause. Adverse events (AEs) were coded and graded according to the NCI Common Terminology Criteria for Adverse Events (version 4.0).
Statistical Design and Analysis
The current study was a randomized phase 2 study of HD IL-2 plus ziv-aflibercept versus HD IL-2 alone. The randomization was 2:1 in favor of the combination arm, using blocked randomization. The randomization was performed by the central data coordination center.
Follow-up was reported based on the reverse KaplanMeier method. The primary endpoint of PFS was measured from the date of randomization until the date of disease progression or death or was censored at the time of last contact. The primary comparison was based on the log-rank test for comparison of PFS. The accrual goal was 105 patients (70 patients on the combination arm and 35 patients on the monotherapy arm). The study design (as planned) had 89% power (with 91 events) to detect a 75% increase in the median PFS (7 months vs 4 months) at the 1-sided significance level of .10. There was no planned interim analysis other than for toxicity considerations.
Laboratory Correlative Studies
Peripheral blood was collected at each clinical site and shipped overnight to the central laboratory in Pittsburgh to be processed. Serum, drawn into red top tubes lacking an anticoagulant, was centrifuged to remove the cell clot, and the serum was aliquoted and frozen at -80°C until testing in batch.
Serum VEGF (baseline and after treatment) and VEGFR2 (baseline only) levels were measured in both study arms using standardized enzyme-linked immunoadsorbent assay kits (R&D Systems Inc, Minneapolis, Minnesota). Assays were performed at the University of Pittsburgh Medical Center Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory, which is accredited by the College of American Pathologists and certified by Clinical Laboratory Improvement Amendments.
RESULTS
The current NCI-sponsored study was initiated in January 2011 by the California Cancer Consortium with Pittsburgh (CCCP) under an N01 contract with participation from multiple sites across the United States. The study was terminated on February 1, 2016, and was short of the originally planned target accrual of 105 patients due to factors related to slow accrual and termination of the NCI N01 grants.
A total of 89 patients were enrolled. Baseline demographics and characteristics are listed in Table 1 .
Available data as of a cutoff date of February 16, 2018, were used, with a median follow-up of 41.4 months (95% CI, 27.9-49.4 months) for all patients, 34.5 months (95% CI, 21.3-51.7 months) for patients being treated on the combination arm, and 41.9 months (95% CI, 39.4-57.7 months) for patients receiving HD IL-2 alone. As described in the Consolidated Standards of Reporting Trials (CONSORT) diagram (Fig. 2) , 5 patients who never initiated the study treatment were excluded. Seven patients (5 in the combination arm and 2 patients in the treatment arm receiving HD IL-2 alone) who were treated but withdrew early without a response assessment were considered as nonresponders in this analysis. The median number of cycles for patients being treated on the combination arm was 3 cycles (range, 1-31 cycles) and was 2 cycles (range, 1-3 cycles) for patients being treated on the monotherapy arm.
Among the 84 treated patients (55 on the combination arm and 29 on the arm receiving HD IL-2 alone), there was significant improvement in PFS in favor of the combination arm. The median (95% CI) was 6.9 (4.1-8.7) months versus 2.3 (1.6-3.5r), logrank P = .002. Figure 3A shows the Kaplan-Meier plot of PFS. No significant difference in OS was noted. The median OS was 26.9 months (95% CI, 14.4-63.6 months) for the combination arm versus 24.2 months (95% CI, 11.3-36.4 months) for the patients treated with HD IL-2 alone. Figure 3B shows the Kaplan-Meier plots for OS. The RR (RECIST) was 22% in the combination arm (4 CRs and 8 partial responses [PRs] ) versus 17% in the arm receiving HD IL-2 alone (1 CR and 4 PRs). The disease control rate (stable disease, PR, or CR) was 65% with the combination arm versus 48% in the single-agent arm.
AEs were consistent with the AE profiles of monotherapy with IL-2 and ziv-aflibercept. Grade 4 events in the combination arm included decreased lymphocytes (41 patients) and platelets (6 patients), renal failure (1 patient), neutropenia (2 patients), hypertension (2 patients), and thromboembolism (1 patient). Toxicity is summarized in Table 2 .
Among 29 treated patients in arm B (the monotherapy arm), the salvage medications received included ipilimumab in 13 patients (45%), anti-PD-1 monotherapy in 9 patients (31%), ipilimumab plus nivolumab in 1 patient (3%), a BRAF inhibitor with or without an MEK inhibitor in 7 patients (24%), dendritic cell vaccine in 3 patients (10%), chemotherapy in 5 patients (17%), and talimogene laherparepvec in 1 patient (3%). Among the 55 patients treated in arm A, 17 patients (31%) received To investigate the impact of VEGF blockade further, we next assessed serum VEGF in the combination arm compared with the patients in the arm receiving HD IL-2 alone. We used the median baseline measures of VEGF and VEGFR2 to establish the cutpoints for "high" and "low." As expected, there was a significant reduction in VEGF levels while patients were receiving treatment (end of course 2) compared with baseline on arm A versus arm B (P<.0001). The median PFS was found to be significantly longer in the combination arm compared with the monotherapy arm, including the high baseline VEGF groups (8.7 months vs 3.1 months; P=.003) and the low baseline VEGF groups (6.9 months vs 4.0 months; P=.02) (Fig. 4A) . Similarly, in our assessment of Cancer November 15, 2018 baseline serum VEGFR2, the median PFS was significantly longer in the combination arm including the high VEGFR2 groups (10.2 months vs 3.9 months; P=.004) and the low VEGFR2 groups (6.1 months vs 1.6 months; P=.0002) (Fig. 4B) .
DISCUSSION
The current study tested the primary hypothesis that combination biotherapy with ziv-aflibercept, as a highaffinity soluble VEGF receptor and potent angiogenesis inhibitor, and HD IL-2 would lead to improved antitumor efficacy compared with HD IL-2 alone. The study met its primary endpoint of significantly improving PFS, but there were no significant differences noted in the secondary endpoints of OS or RR, thereby undermining the primary endpoint of outcome. The lack of significant differences in OS may be understood taking into account the limited phase 2 study sample size as well as the therapeutic salvage patterns observed in patients who eventually developed disease progression. Therefore, we expected survival benefits from active agents received as salvage in both study arms. RRs were numerically higher for the combination arm compared with the single-agent arm (22% vs 17%), but were not significantly different, which also may be a limitation of the phase 2 sample size herein.
The systemic treatment of metastatic melanoma has undergone a major transformation over the past 7 years with the development of novel molecularly targeted kinase inhibitors and immune checkpoint blockers. [15] [16] [17] [18] However, to our knowledge, the majority of patients Cancer November 15, 2018 still do not achieve long-term disease remission and control and continue to require salvage systemic therapy. Overall, recent 5-year OS data from a phase 2 trial of dabrafenib and trametinib for patients with BRAF V600-mutant metastatic melanoma reported a median OS of 25.0 months and a 5-year OS rate of 28% in patients receiving the approved label dose. 20 Similarly, a recent OS analysis of the phase 3 KEYNOTE-006 trial, which tested pembrolizumab monotherapy, reported a 33-month OS rate of 50%. 21 In the phase 3 CheckMate 067 trial, the 3-year OS rate was 52% and 58%, respectively, in patients treated with nivolumab monotherapy or nivolumab plus ipilimumab. 16 Therefore, at least 50% of patients with metastatic melanoma who are treated with kinase inhibitors and/or immune checkpoint inhibitors will require second-line or subsequent salvage systemic therapy whereas HD IL-2 in combination with ziv-aflibercept would be worth considering in candidate patients.
Baseline serum VEGF as a marker of immune resistance was associated with nonresponse to HD IL-2. 6 In the current analysis, patients with high levels of VEGF and VEGFR2 were found to have a significantly better clinical outcome, as measured by PFS, when treated on the combination arm compared with HD IL-2 monotherapy. Similarly, improved PFS also was observed with the combination among patients with low VEGF and VEGFR2 levels. These findings support the initial hypothesis related to reversing immune suppression mediated by VEGF, and most likely also suggest an additive antiangiogenic clinical impact with ziv-aflibercept, a known clinically active agent in melanoma, as we previously reported. 13 VEGFA, typically referred to as VEGF, is present in a variety of different splice isoforms, 2 of which are freely circulating (VEGF 121 and VEGF 165 ). 7 VEGF can signal through several different receptors: VEGFR1, VEGFR2, and VEGFR3. The major signaling receptor for VEGF-mediated angiogenesis is believed to be VEGFR2, also called kinase-insert domain-containing receptor in humans or fms-like tyrosine kinase (flt) 1 in mice.
7 VEGFR3 is involved mainly in lymphangiogenesis, although there is growing evidence that it also can be involved in angiogenesis. To the best of our knowledge, the role of VEGFR1 still is unknown. However, there is growing interest in VEGFR1, in part because of its role in the mobilization of several the bone marrowderived circulating cell populations. 7 To our knowledge, high circulating VEGF levels are prognostic of poor PFS and OS regardless of treatment, but they do not appear to be predictive of clinical outcomes of therapy with VEGF inhibitors in various solid tumors. 22 Similarly, in patients with melanoma, there is increased expression of VEGF in metastatic melanoma biopsies, 23 a correlation between VEGF levels and tumor burden, and a correlation between increased serum concentrations of angiogenic factors and disease progression and survival. 24 In the current study, a clinical benefit was observed regardless of the baseline VEGF or VEGFR2 levels, thereby supporting a prognostic rather than a predictive value.
The enhanced antitumor activity observed with the combination of antiangiogenic and immunotherapeutic agents has been reported with other agents in patients with metastatic melanoma. A phase 1 study combining anti-VEGF blockade with bevacizumab and CTLA4 blockade with ipilimumab reported a RR of approximately 20% and a disease control rate of 67.4%. 25 The median survival was 25.1 months. Tumor biopsies obtained while patients were receiving treatment demonstrated significant infiltration by CD8-positive T cells and CD163-positive dendritic macrophages within tumor vessel endothelium, with enhanced CD31 staining noted at the interendothelial junctions. These data suggest that vessels were adapted for efficient lymphocyte trafficking in which CD31 may impact adhesive and signaling functions for vascular cellular extravasation. 26 Peripheral blood flow cytometry demonstrated increased CD4-positive and CD8-positive T cells that were CCR7 (positive/negative)/CD45RO (positive) and increased circulating memory cell phenotypes compared with ipilimumab alone, further supporting the immune modulator impact of VEGF inhibition. 25 This study led to a national cooperative group randomized trial testing ipilimumab and bevacizumab versus ipilimumab alone (E3611; ClinicalTrials.gov identifier NCT01950390). Similarly, a phase 2 study of bevacizumab and high-dose interferon-α-2b in patients with metastatic melanoma reported a response rate of 24%. 27 More recently, programmed death-ligand 1 (PD-L1) blockade with atezolizumab in combination with VEGF inhibition with bevacizumab has shown promising activity in phase 2 to 3 trial testing in patients with metastatic renal cell carcinoma, thereby supporting the use of atezolizumab plus bevacizumab as a first-line treatment option in these patients. 28 These phase 3 data in patients with metastatic renal cell carcinoma are consistent with data from the current study and support a role for VEGF inhibition as an important component of a combination immunotherapeutic strategy.
Efforts to overcome the limitations of the short half-life and pleiotropic systemic effects of systemic IL-2 led to the development of interesting molecules such as 30 The current study data may support a future combination strategy of NKTR-214 or ALKS-4230 and VEGF inhibition in the second-line or subsequent treatment setting in patients with advanced melanoma as an outpatient and potentially less toxic regimen.
CONCLUSIONS
In the current study, the combination of ziv-aflibercept and HD IL-2 significantly improved PFS compared with the use of IL-2 alone, thereby meeting the study's primary endpoint. The regimen was relatively safe and manageable. The combination was found to be superior to monotherapy in patients with high and low levels of serum VEGF and VEGFR2. The findings of the current study provide support for the further examination of combination strategies of VEGF inhibitors and immunotherapy.
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